Breaking News

Brammer Bio Expands Cell and Gene Therapy Capacity

Invests $50 million at two sites, partners with Pall for suspension and adherent platform technologies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Brammer Bio, a cell and gene therapy contract developing and manufacturing organization (CDMO), has expanded its early clinical phase facility in Alachua, FL and its new Phase III and commercial facility in Cambridge, MA. The company is investing $40 million to enable scale-up through Phase III and strengthen commercial client support in Cambridge. At Alachua’s process development and pilot facility, Brammer invested $10 million to double cGMP manufacturing capacity. Both sites will feature Pall...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters